Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-20-078271
Date:2020-06-25
Issuer: KALA PHARMACEUTICALS, INC. (KALA)
Original Submission Date:

Reporting Person:

BAZEMORE TODD
C/O KALA PHARMACEUTICALS, INC.
490 ARSENAL WAY, SUITE 120 WATERTOWN, MA 02472

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-06-25 A 19,000 a $0.00 29,000 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 grant of restricted stock units ("rsus") under the issuer's 2017 equity incentive plan. each rsu represents a contingent right to receive one share of the issuer's common stock. subject to the reporting person's continued employment with the issuer, the rsus will vest as to 50% of the shares underlying the rsus on june 25, 2021 and the remaining 50% of the shares underlying the rsus on june 25, 2022.
f2 includes 19,000 unvested rsus.
WhaleWisdom Logo

Elevate your investments